Histogen (Histogen) Scaled Net Operating Assets : -0.01 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Histogen Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Histogen's operating assets for the quarter that ended in Sep. 2023 was $1.24 Mil. Histogen's operating liabilities for the quarter that ended in Sep. 2023 was $1.41 Mil. Histogen's Total Assets for the quarter that ended in Jun. 2023 was $13.54 Mil. Therefore, Histogen's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2023 was -0.01.

Histogen Scaled Net Operating Assets Historical Data

The historical data trend for Histogen's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Histogen Scaled Net Operating Assets Chart

Histogen Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

-13.56

1.86

0.42

0.22

Histogen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Scaled Net Operating Assets	Get a 7-Day Free Trial													0.30	0.27	0.28	0.34	-0.01

Competitive Comparison of Histogen's Scaled Net Operating Assets

For the Biotechnology subindustry, Histogen's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Histogen's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Histogen's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Histogen's Scaled Net Operating Assets falls into.

Histogen Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Histogen's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(6.964	-	1.066)	/	27.245
=	0.22

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	19.073	-	12.109
=	6.964

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	5.697	-	4.384	-	0.247
=	1.066

Histogen's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2023 )
=	(Operating Assets (Q: Sep. 2023 )	-	Operating Liabilities (Q: Sep. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(1.244	-	1.413)	/	13.542
=	-0.01

where

	Operating Assets		(Q: Sep. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.817	-	4.573
=	1.244

	Operating Liabilities		(Q: Sep. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	1.413	-	0	-	0
=	1.413

Histogen Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Histogen's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (Histogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Executives

Joyce Reyes	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann	director	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson	officer: See Remarks	9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson	director, 10 percent owner	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton	officer: See Remarks	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang	director	12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich	officer: See Remarks	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall	officer: EVP, COO & CFO	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127